货号价格

VEG-HM421B-100μg / 询价

VEG-HM421B-500μg / 询价

VEG-HM421B-500μgx2 / 询价

Biotinylated Human VEGF121 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Biotinylated Human VEGF121 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Ala27-Arg147.[Accession | P15692-9]

分子量大小(Molecular Weight)

The protein has a predicted MW of 17 kDa. Due to glycosylation, the protein migrates to 18 kDa and 22-25 kDa under reduced (R) condition, 30 kDa and 32-40 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

纯度(Purity)

> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 24 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Biotinylated Human VEGF121 on Tris-Bis PAGE under reduced (R) condition and Non reducing (N) condition. The purity is greater than 95%.

ELISA Data

Immobilized Human VEGF R1, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human VEGF121, His Tag with the EC50 of 16.5ng/ml determined by ELISA.

背景(Background)

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.

分子别名(Synonyms)

VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609

文献(References)

(1)Rosen, L. S. VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances[J]. The Oncologist, 2005, 10(6):382-391.